Norgine partners with Arc Medical to commercialize and distribute ENDOCUFF VISION

Norgine and Arc Medical Design Ltd. today announced a partnership that will see Norgine commercialising and distributing ENDOCUFF VISION^™, a Class 1 sterile medical device used in colonoscopy, across a number of major European markets, Australia and New Zealand. Norgine's first launch of ENDOCUFF VISION^™ will take place in the UK Q2 2015.

ENDOCUFF VISION^™ is a single use, sterile endoscopic overtube, which fits onto the distal end of most endoscopes, and has been designed to improve tip control during extubation and enhance mucosal vision in patients with diseases of the colon, including colorectal cancer. The improved visualisation of lesions has been shown to result in an increase in both the Adenoma Detection Rate (ADR) and Mean Adenomas per Patient (MAP) rate.

Colorectal cancer is the second most common cause of cancer-related mortality in the world; nearly 1.4 million new cases of colorectal cancer were diagnosed worldwide in 2012 and 412,000 people are diagnosed with it every year in Europe.

Peter Stein, Chief Executive Officer Norgine, commented, "We are excited about our new partnership with Arc Medical and the promotion of ENDOCUFF VISION^™, a device which not only leads to a significant increase in lesion detection, but also ensures a quality colonoscopy and avoids the need for repeat procedures - thus significantly improving the patient experience. This partnership is a further example of Norgine's commitment to improving quality in colonoscopy and adds to our existing bowel cleansing portfolio."